SCHEMBL17528484

SCHEMBL17528484

CCCCCCCCCCCCCCOCCOP(=O)(O)OCC(O)CO

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.59
LPAR5 Q9H1C0 1/20 0.58
P2RY10 O00398 2/20 0.51
PLA2G2C Q5R387 3/20 0.49
PLA2G2A P14555 1/20 0.48
LPAR3 Q9UBY5 5/20 0.47
LPAR1 Q92633 4/20 0.47
SELP P16109 1/20 0.46
MEN1 O00255 1/20 0.45
THRB P10828 1/20 0.45
HTT P42858 1/20 0.45
KMT2A Q03164 1/20 0.45
MAPT P10636 1/20 0.45
LPAR2 Q9HBW0 2/20 0.44
CYP3A4 P08684 1/20 0.44
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23016732 0.91 USP2 (0.57) USP2LPAR5P2RY10PLA2G2CLPAR3
SCHEMBL10664178 0.91 USP2 (0.57) USP2LPAR5P2RY10PLA2G2CLPAR3
SCHEMBL17528452 0.91 USP2 (0.57) USP2LPAR5P2RY10PLA2G2CLPAR3
SCHEMBL28659331 0.91 USP2 (0.57) USP2LPAR5P2RY10PLA2G2CLPAR3
SCHEMBL30888163 0.91 USP2 (0.57) USP2LPAR5P2RY10PLA2G2CLPAR3
SCHEMBL31347426 0.90 LPAR5 (0.73) USP2LPAR5P2RY10PLA2G2CLPAR3
SCHEMBL31347422 0.90 LPAR5 (0.73) USP2LPAR5P2RY10PLA2G2CLPAR3
SCHEMBL31347452 0.90 LPAR5 (0.73) USP2LPAR5P2RY10PLA2G2CLPAR3
SCHEMBL31347419 0.90 LPAR5 (0.73) USP2LPAR5P2RY10PLA2G2CLPAR3
SCHEMBL31347436 0.90 LPAR5 (0.73) USP2LPAR5P2RY10PLA2G2CLPAR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180064813-A1 Oral Composition for Delivery of Drugs and Other Substances AVANTI POLAR LIPIDS, LLC 2018-03-08 US disclosed
US-9872908-B2 Oral composition for delivery of drugs and other substances AVANTI POLAR LIPIDS, INC. (US) 2018-01-23 US disclosed
US-20160166699-A1 Oral Composition for Delivery of Drugs and Other Substances AVANTI POLAR LIPIDS, LLC 2016-06-16 US disclosed
WO-2016025401-A1 ORAL COMPOSITION FOR DELIVERY OF DRUGS AND OTHER SUBSTANCES AVANTI POLAR LIPIDS, INC. (US) 2016-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160166699-A1 Oral Composition for Delivery of Drugs and Other Substances MGLL, SGMS2, LIPA USP2 3558/4885LPAR5 68/4885P2RY10 397/4885
US-20180064813-A1 Oral Composition for Delivery of Drugs and Other Substances MGLL, SGMS2, LIPA USP2 3558/4885LPAR5 68/4885P2RY10 397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.